\documentclass{beamer}
\usepackage{pgfplotstable, pgfplots, grffile}
\usepackage{booktabs, colortbl, array, graphicx}
\pgfplotsset{compat=newest}
\usetheme[numbering=fraction,progressbar=foot,block=fill]{metropolis}
\setsansfont{Noto Sans}
\mode<presentation>

\makeatletter
\newcommand{\thickhline}{%
    \noalign {\ifnum 0=`}\fi \hrule height 1pt
    \futurelet \reserved@a \@xhline
}

\title{Oral Qualifying Exam}
\author{Daniel Nachun}

\begin{document}
\begin{frame}
    \titlepage
\end{frame}

\begin{frame}{My Journey So Far}
    \begin{itemize}
        \item May 2008 - Graduated from Westside High School in Omaha, Nebraska
        \item June 2012 - Received BA in Biology from Williams College w/ concentrations in neuroscience and biochemistry
        \item September 2012 - Started UCLA NSIDP
        \item June 2013 - Joined lab of Chris Evans studying addiction in mice
        \item July 2015 - Left Evans lab and joined Giovanni Coppola's lab
    \end{itemize}
\end{frame}

\begin{frame}{Neurological and Psychiatric Disorders}
    \begin{itemize}
        \item 13 of the top 25 sources of global disease burden 
        \item 53 million people had dementia 2013
        \item 253 million people had depression in 2013
        \item Treatments for neurodegeneration can only slow symptoms
        \item Treatments for depression not universally effective
    \end{itemize}
\end{frame}

\begin{frame}{Studying the CNS}
    \begin{itemize}
        \item Highly inaccessible
        \item Composed mostly of delicate postmitotic cells 
        \item Quantification of symptoms is very difficult - relies on self-reporting or clinical scales
        \item Disorders tend to change fairly slowly over time
        \item Biomarkers can be used to overcome some of these limitations
    \end{itemize}
\end{frame}

\begin{frame}{Post-Mortem Studies}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Advantages}
        \begin{itemize}
            \item Can directly study affected CNS tissues
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Disadvantages}
        \begin{itemize}
            \item Biased towards more advanced stages of disease
            \item Quality of biological material is often lower than in vivo samples
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Cerebrospinal Fluid}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Advantages}
        \begin{itemize}
            \item CSF interacts directly with CNS tissue
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Disadvantages}
        \begin{itemize}
            \item Collection is fairly invasive and dangerous
            \item Small numbers of cells
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Peripheral blood}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Advantages}
        \begin{itemize}
            \item Readily accessible and easy to extract
            \item Can be sampled repeatedly
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Disadvantages}
        \begin{itemize}
            \item Actively renewing cell population doesnâ€™t accumulate changes
            \item Less metabolically active than cells of CNS
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{In vitro methods}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Advantages}
        \begin{itemize}
            \item Cells can be acquired directly from patients
            \item Can be differentiated into neurons and other CNS cell types
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Disadvantages}
        \begin{itemize}
            \item Biological age may be too young for adult onset disease
            \item Cannot recapitulate network properties of CNS
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Animal models}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Advantages}
        \begin{itemize}
            \item Any tissue can be accessed for study including CNS
            \item Can be genetically engineered
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Disadvantages}
        \begin{itemize}
            \item Does not always translate to humans
            \item Sample sizes are often very small
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Biological Materials}
    \begin{itemize}
        \item Peptides - protein expression
        \item RNA - gene expression
        \item DNA - genetic variation, methylation, histone modifications, chromosome structure
        \item Gene expression and DNA methylation have the most mature and scalable technologies
    \end{itemize}
\end{frame}

\begin{frame}{Microarrays vs. Next Generation Sequencing}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Microarrays}
        \begin{itemize}
            \item Low cost
            \item Faster acquisition and analysis
            \item Noisier, especially at low levels
            \item Available for many years
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{NGS}
        \begin{itemize}
            \item Higher cost, but dropping
            \item Slower acquisition and analysis
            \item Lower noise 
            \item Only available more recently
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Friedreich's Ataxia (FRDA) dataset}
    \begin{itemize}
        \item FRDA is a rare, autosomal recessive Mendelian disorder
        \item Symptoms - problems with gait and voluntary movement, cardiac hypertrophy, diabetes
        \item Very young onset - typically around puberty
        \item Caused by GAA repeat expansion in frataxin (FXN) - reduces expression 65-95\%, probably driven by epigenetics
        \item FXN is essential for the formation of iron-sulfur clusters used in mitochondria and breakdown of reactive oxygen species
        \item 409 patients, 226 heterozygous carriers, 90 controls
    \end{itemize}
\end{frame}

\begin{frame}{Dementia dataset}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Alzheimer's Disease (AD)}
        \begin{itemize}
            \item Most common form of dementia
            \item Characterized by memory loss and cognitive impairment
            \item Genetic risk factors: ApoE, APP, PSEN1 and PSEN2
            \item Risk of onset doubles every 5 years after age of 65
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Mild Cognitive Impairment (MCI)}
        \begin{itemize}
            \item Similar symptoms to AD, but milder
            \item Sometimes viewed as a transitory phase between normal aging and dementia
            \item Roughly 50\% of MCI patients eventually develop dementia
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}{Dementia dataset continued}
    \textbf{Frontotemporal Dementia (FTD)}
    \begin{itemize}
        \item Second most prevalent form of dementia
        \item Much earlier onset than AD - 50-60 years old
        \item Symptoms: Changes in executive function and language difficulties
        \item Genetic risk factors: C9orf72, GRN, MAPT, TDP-43, FUS
        \item Subdivided into behavioral variant FTD (bvFTD), semantic dementia (SD) and progressive non-fluent aphasia (PNFA)
    \end{itemize}
\end{frame}

\begin{frame}{Dementia dataset}
    \begin{columns}[t]
    \begin{column}{0.5\textwidth}
        \textbf{Movement Disorders}
        \begin{itemize}
            \item Amyotrophic lateral sclerosis (ALS), Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP)
            \item Comorbid with some cases with FTD
            \item Pathology and genetic risk factors overlap with FTD
        \end{itemize}
    \end{column}
    \begin{column}{0.5\textwidth}
        \textbf{Clinically Normal}
        \begin{itemize}
            \item Younger subjects with family history of dementia
            \item Some have mutations in linked to dementia
        \end{itemize}
    \end{column}
    \end{columns}
\end{frame}

\begin{frame}
    \frametitle{Sample Sizes}
    \renewcommand{\arraystretch}{1.3}
    \fontsize{8}{9.5}\selectfont    
    \setlength{\tabcolsep}{2pt}
    \begin{center}
        \vspace{0.4cm}
        \centerline{
        \pgfplotstabletypeset[
        col sep=comma, 
        string type, 
        ignore chars={"}, 
        every even row/.style={before row={\rowcolor{lightgray}}},
        every first column/.style={column type={l}},
        every head row/.style={before row=\thickhline, after row=\thickhline},
        every last row/.style={before row=\thickhline, after row=\thickhline}
        ]
        {diagnosis_summary.csv}}
    \end{center}
\end{frame}

\begin{frame}{Major depressive disorder (MDD) dataset}
    \begin{itemize}
        \item MDD symptoms: low self-esteem, loss of interest in activities, low energy, and suicidal thoughts
        \item 40-50\% is heritable, 50-60\% environmental - identification of risk factors has been largely unsuccessful
        \item Pharmacological treatments include TCAs, SSRI/NRIs, MAOIs and atypical antidepressants - less than 50\% of patients are treated
        \item Last line of treatment - electroconvulsive therapy (ECT), wake therapy and ketamine
    \end{itemize}
\end{frame}

\begin{frame}{MDD dataset continued}
    \begin{itemize}
        \item Study design: treat patients with ECT, wake therapy, or ketamine
        \item Collect RNA and DNA at baseline, after first treatment, after end of treatment, and 6 months later
        \item Non-responders not usually sampled at last time point
        \item Controls also collected at first time point
    \end{itemize}
\end{frame}

\begin{frame}{Specific Aim 1: Gene Expression Biomarkers}
    \begin{itemize}
        \item Goal: Identification of gene expression biomarkers in blood
        \item Biomarker candidates - genes whose expression levels are significantly associated with disease status, genotype, or continuous trait
        \item Approaches: Single gene analysis, network analysis, predictive modeling
        \item Workflow developed with FRDA dataset
    \end{itemize}
\end{frame}

\begin{frame}
    \frametitle{Aim 1a: Single Gene Analysis}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 1}
                    \footnotesize
                    For categorical variables: linear modeling with limma, assess significance with EBAM approach from siggenes \\
                    \vspace{\baselineskip}
                    For continuous variables: correlation (preferably biweight mid-correlation)
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/baseline_lumi/volcano_pca.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}
    \frametitle{Enrichment Analysis}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 2}
                    \footnotesize
                    Enrichr allows the user to submit a gene list to multiple databases (i.e. GO Biological Process, KEGG, Reactome)\\
                    \vspace{\baselineskip}
                    Enrichment scores calculated from hypergeometric overlap test
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/baseline_lumi/pca.enrichr.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}
    \frametitle{Correlation}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 3}
                    \footnotesize
                    Gene expression can be correlated directly with continuous traits\\
                    \vspace{\baselineskip}
                    P-values calculated using Studentâ€™s asymptotic approach\\
                    \vspace{\baselineskip}
                    Biweight midcorrelation is more outlier resistant than Pearsonâ€™s correlation
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA_GAA/TMOD1.pdf}
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA_GAA/EIF1.pdf}
                \end{figure}
                \vspace{-0.6cm}
                \begin{figure}
                    \centering
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA_GAA/DBNDD1.pdf}
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA_GAA/DGKD.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}
    \frametitle{Overlap Analysis}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 4}
                    \footnotesize
                    Other datasets available for both dementia and depression, including full transcriptomes\\
                    \vspace{\baselineskip}
                    Rank-rank hypergeometric overlap determines best possible overlap value\\
                    \vspace{\baselineskip}
                    Heatmaps used to visualize overlaps between different contrasts and datasets
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/overlap/overlap.heatmap.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}{Alternative Approaches}
    \begin{itemize}
        \item Fully non-parametric permutation based DE analysis with Significance Analysis of Microarray (SAM) or EBAM
        \item Assess whether log fold change difference is above a specific threshold - T-test RElative to A Threshold (TREAT)
    \end{itemize}
\end{frame}

\begin{frame}{Aim 1b: Network Analysis}
    \begin{itemize}
        \item Genes are often co-expressed - must have some covariance structure
        \item Weighted Gene Co-expression Network Analysis (WGCNA) computes correlations between all genes and clusters into modules based on Manhattan distance in dissimilarity topological overlap matrix (TOM)
        \item Eigengenes are calculated from first principal component of each module
    \item Hub genes are biomarker candidates
    \end{itemize}
\end{frame}

\begin{frame}
    \frametitle{Sample Network Dendrogram and Modules}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 5}
                    \footnotesize
                    Dendrogram is visualization of clustering structure in dissimilarity TOM\\
                    \vspace{\baselineskip}
                    Colors represent module assignments based on dynamicTreeCut\\
                    \vspace{\baselineskip}
                    Modules with eigengenes with correlation > 0.8 were merged
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/WGCNA/module_eigengene_clustering.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}
    \frametitle{Significant Eigengenes}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \footnotesize
                \begin{block}{Figure 6}
                    Eigengene significance assessed with linear model ANOVA for categorical variables, biweight midcorrelation for continuous\\
                    \vspace{\baselineskip}
                    Non-parametric testing - Kruskal-Wallis ANOVA for categorical variables, Spearman correlation for continuous
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA/black.pdf}
                    \includegraphics[width=0.5\textwidth]{../../FRDA project/WGCNA/brown.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}{Aim 1b: Network Analysis}
    \begin{itemize}
        \item Gene modules will be submitted to Enrichr for GO and pathway enrichment analysis
        \item Protein-protein interactions will be found with InWeb and BioGrid
        \item Validation - consensus networks for sufficiently large datasets
        \item Alternatives - nonlinear relationships can be studied with mutual information based networks (ARACNE, MRNET, MIC) or polynomial spline regression but very computationally intensive
    \end{itemize}
\end{frame}

\begin{frame}{Aim 1c: Predictive Modeling}
    \begin{itemize}
        \item Build models to predict categorical variable (classification) or continuous variables (regression) - top ranked features are biomarkers
        \item More popular models: discriminant analysis, support vector machines (SVM), random forest and tree-based methods, neural networks
        \item Factors to consider: prediction performance, number of parameters, computational feasibility
        \item Powerful and flexible framework provided by caret package
    \end{itemize}
\end{frame}

\begin{frame}{Feature Selection}
    \begin{itemize}
        \item Transcriptome data usually has many more features than samples - prone to overfitting
        \item Many features are redundant or noisy and must be removed
        \item Metrics to rank features - differential expression, correlation, distance measures (i.e. Kolmogorov-Smirnoff)
        \item Correlation Adjusted T-scores (CAT) and Correlation Adjusted coRrelation (CAR) - feature ranking that accounts for correlation between features
    \end{itemize}
\end{frame}

\begin{frame}
    \frametitle{Classification}
        \begin{figure}
            \centering
            \includegraphics[width=1.0\textwidth]{../../FRDA project/classification/svm.rfe.accuracies.pdf}
        \end{figure}
        \begin{block}{Figure 7}
            \footnotesize
            SVM with linear kernel has performed well with FRDA data on subsets of CAT-ranked genes\\
            \vspace{\baselineskip}
            Model performance assessed with Cohenâ€™s kappa adjusted with 0.632 method in 25 boostrapped samples
        \end{block}
        %\begin{columns}
            %\begin{column}{0.35\textwidth}
            %\end{column}
            %\begin{column}{0.65\textwidth}
            %\end{column}
        %\end{columns}
\end{frame}

\begin{frame}
    \frametitle{Regression}
        \begin{columns}
            \begin{column}{0.35\textwidth}
                \begin{block}{Figure 8}
                    \footnotesize
                    SVM with polynomial kernel has done well predicting age and GAA length in FRDA data on subsets of CAR-ranked genes\\
                    \vspace{\baselineskip}
                    Model performance assessed with RMSE and R2 adjusted with 0.632 method in 25 bootstrapped samples 
                \end{block}
            \end{column}
            \begin{column}{0.65\textwidth}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/GAA_regression/svm.rmse.pdf}
                \end{figure}
                \vspace{-0.7cm}
                \begin{figure}
                    \centering
                    \includegraphics[width=1.0\textwidth]{../../FRDA project/GAA_regression/svm.rsquared.pdf}
                \end{figure}
            \end{column}
        \end{columns}
\end{frame}

\begin{frame}{Aim 1c: Predictive Modeling}
    \begin{itemize}
        \item Validation - test predictions on other data; for large datasets, build models and test them with my data
        \item Alternative approaches - try other models using caret framework, use other feature ranking methods including some implemented by ClassifyR
    \end{itemize}
\end{frame}

\begin{frame}{Specific Aim 2: Identify DNA methylation biomarkers in blood}
    \begin{itemize}
        \item DNA methylation is a marker of gene suppression - increased methylation leads to reduced expression
        \item Data can usually be treated equivalently to expression data - beta-values are restricted to range of 0 to 1
        \item Illumina Human 450k and  EPIC arrays have individual probes corresponding to genes, intergenic CpG islands and other areas
        \item RnBeads package makes it easy to collapse data to gene bodies or promoters (1.5kb upstream to 0.5kb downstream of TSS)
    \end{itemize}
\end{frame}

\begin{frame}{Adaptations for DNA methylation}
    \begin{itemize}
        \item Work with preliminary datasets indicates that only minimal changes need to be made to adapt gene expression workflow for methylation
        \item RnBeads collapses data Ensembl IDs - must be annotated with symbols and other information using biomaRt
        \item Soft-thresholding for network analysis may need to be adjusted
        \item Methylation data will also be submitted to methylation biological clock 
    \end{itemize}
\end{frame}

\begin{frame}{Specific Aim 3: Integration of gene expression and methylation data}
    \begin{itemize}
        \item Goal: Examine the relationship between gene methylation and expression, and determine if disease affects this relationship
        \item Single gene analysis: correlate linear modeling coefficients, correlate expression and methylation of individual genes
        \item Network analysis: consensus network between methylation and expression
        \item Predictive modeling: train regression models from methylation data to predict gene expression
    \end{itemize}
\end{frame}

\begin{frame}{Timeline}
    \begin{itemize}
        \item Next committee meeting - 8-12 months
        \item Graduation - middle to end of 2018 - 6 years total for Ph.D. (the average completion time for NSIDP), 3 with Giovanni
        \item Interested in both bioinformatics post-docs and industry positions - stay in California
    \end{itemize}
\end{frame}

\begin{frame}{Acknowledgements}
    \begin{itemize}
        \item Margaret Chu
        \item Committee members!
        \item Coppola lab: Fuying Gao, Tom Crisman, Zhongan Yang, Deepika Dokuru, Victoria Van Berlo, Kevin Wojta, Doxa Chatzopoulou
        \item Geschwind lab: Jill Haney, Vivek Swarup
        \item Ophoff lab: Anil Ori
        \item Eliza Congdon and Depression Grand Challenge
        \item Childrenâ€™s Hospital of Philadelphia - David Lynch, Charlie Isaacs
        \item Friedreichâ€™s Ataxia Research Alliance - Jen Farmer
    \item UCSF Center for Memory and Aging
    \end{itemize}
\end{frame}


\end{document}
